UPB
Upstream Bio, Inc.- Healthcare
- Biotechnology
- $312M market cap
Forecast run · Sep 14, 2026Upside rank 633 of 3,136
Model Signal
ForecastQ Daily Probabilities
52.5%
37.9%
35.7%
Analyst Consensus
Recommendation2.40/5 Buy
Last price$5.73
Price target$20.00
Implied move+249.0%
Analysts5
ForecastQ Portfolios
UPB is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.